Table of Contents
More than six in ten people with alcohol use disorder, when asked directly, say they would be willing to participate in a psychedelic therapy trial. That figure comes from a mixed-method study published in Psychopharmacology in June 2026, which surveyed 112 participants already enrolled in clinical trials or receiving care at addiction outpatient services in Germany. The finding matters not because it settles anything about efficacy, but because it tells researchers and clinicians something they rarely ask for: what patients themselves think before a single dose is given.
What the Study on Psychedelic Therapy for Alcohol Use Disorder Actually Did
The research team, led by Julian Kirsch and colleagues, recruited participants from two non-psychedelic clinical trials (n = 102) and from addiction outpatient services (n = 10). The quantitative portion used a four-item questionnaire covering awareness of psychedelic research, expectations of its promise, and willingness to participate in a future psychedelic trial. The qualitative portion conducted semi-structured interviews with ten outpatient participants, analyzing their responses thematically to understand what shaped their attitudes.
Of the 112 participants, 62.5 percent were already aware that psychedelic research exists, and 64.3 percent expressed willingness to try such a therapy. Binary logistic regression found that willingness was significantly associated with higher expectations of research success, with an odds ratio of 3.30 (p less than .001). Age and baseline knowledge alone did not significantly predict willingness to participate in a psychedelic therapy trial.
What Participants Said, and What They Feared About Psychedelic-Assisted Treatment
The qualitative interviews added texture to those numbers. Participants described a wide spectrum of attitudes. Some were genuinely hopeful, particularly those who felt that conventional treatments had not worked for them. Others were neutral, waiting to see more evidence before committing to an opinion. A meaningful number expressed hesitation rooted in specific fears: concern about becoming addicted to a psychedelic substance, fear of losing control during a session, and wariness shaped by their own or others’ difficult histories with substances.
Media exposure played a notable role in shaping perceptions in both directions. Positive coverage raised expectations; negative or sensationalized coverage deepened anxiety. Personal and social experiences with substance use also colored how people interpreted the idea of intentionally taking a psychedelic in a clinical setting.
Expectation of benefit emerged as the central factor influencing openness, more than knowledge, age, or any other variable measured in the study.
Limitations the Authors Name Directly
The researchers are candid about what their study cannot tell us. The clinical trial sample carries participation bias: people who volunteer for addiction research may already be more open to novel treatments than the broader AUD population. The study also did not measure prior psychedelic use, which could meaningfully influence attitudes and expectations. The outpatient sample was small, only ten interviews, and the findings are hypothesis-generating rather than conclusive.
The authors conclude that thorough informed consent, specifically consent that addresses both expectations and misconceptions about addiction potential and risk, will be essential for ethically conducting future psychedelic clinical trials in AUD populations. Openness exists, but it is conditional, and conditions deserve honest conversation.
Why This Research Fills a Quiet Gap in AUD Treatment Research
Most early-phase psychedelic research focuses on outcomes: reduction in drinking days, craving scores, sustained remission. This study asks a prior question: do the people most affected by AUD actually want this kind of treatment, and what would need to be true for them to say yes? Understanding patient attitudes toward psychedelic therapy before trials scale is not a soft concern. Enrollment, retention, and therapeutic alliance all depend on it. A treatment that works in controlled conditions but that most patients fear or distrust will not translate into public health benefit at any meaningful scale.
Alcohol use disorder, as the authors note, carries an elevated mortality risk with a relative risk of approximately two in non-clinical samples and roughly four in clinical populations. Only a small fraction of those affected, between 0.3 and 13.8 percent globally by WHO estimates, ever seek treatment at all. Any serious attempt to address that gap requires understanding not just biology, but the human being sitting across the consultation table.
Does prior knowledge of psychedelic research predict willingness to try it for AUD?
No. The study found that awareness of psychedelic research alone did not significantly predict willingness to participate in a psychedelic therapy trial. What predicted willingness was the expectation that psychedelic research would prove successful, not how much a person already knew about it. This distinction matters for how clinicians approach conversations with patients: sharing information is necessary, but addressing expectations and perceived therapeutic potential may be more decisive in shaping openness to psychedelic-assisted treatment for alcohol use disorder.
What setting do AUD patients prefer for psychedelic therapy?
The study asked participants who expressed willingness whether they would prefer group therapy, individual therapy, or had no preference. The four-item questionnaire included this preferred setting question as part of the quantitative assessment, though the primary published findings center on the predictors of willingness itself. Researchers noted that understanding setting preferences is relevant to designing future psychedelic clinical trials in ways that align with what patients actually want.
Openness Is a Threshold, Not a Destination
There is something quietly significant about a person living with the weight of alcohol use disorder saying, yes, I would try this. That willingness did not appear because someone handed them a brochure. It emerged from expectation, from a hope, however fragile, that something different might be possible. Hope is not a small thing. It is often the first movement on the inner path.
And yet the fears these participants named, addiction to another substance, loss of control, distrust shaped by a lifetime of complicated relationships with substances, are not obstacles to be dismissed. They are invitations for the kind of honest, unhurried informed consent that treats a person as a full human being rather than a trial subject. That is where the sacramental and the clinical can meet: in the quality of presence a practitioner brings before anything is ingested.
This study does not tell us whether psilocybin or any psychedelic will prove effective for AUD at scale. What it tells us is that the people who most need new options are already listening. That is a responsibility worth taking seriously.
If you or someone you love is navigating a difficult relationship with alcohol, we welcome you to the Grounding station of the Golden Path, a space for honest self-assessment, harm-reduction resources, and the steady companionship of a community that holds no judgment. You do not have to have answers to belong here.
May love guide the hearts of all beings.
